The September 17 call is the key near-term catalyst — traders should watch for cash runway updates, partnership or financing announcements, and clinical data on lacutamab or IPH4502. The stock may be volatile around the call given the prior going-concern warning.
Price Chart
Executive Summary
Innate Pharma filed a 6-K announcing a conference call on September 17, 2026, to discuss first-half 2026 financial results and a business update. This is a routine scheduling announcement with no financial data or material news disclosed, but the upcoming call may provide critical updates on cash runway and pipeline progress given the prior 20-F's going-concern warning.
Key Facts
- Innate Pharma will host a conference call on September 17, 2026 at 2:00 PM CEST / 8:00 AM EDT for first-half 2026 results and business update.
- Participants include CEO Jonathan Dickinson, CMO Markus Jensen, COO Yannis Morel, and CFO Frédéric Lombard.
- No financial results, guidance, or material clinical data were disclosed in this filing.
- The prior 20-F (filed April 1, 2026) highlighted a critical funding gap and going-concern risk, making the upcoming call a key catalyst.
Financial Impact
No financial figures disclosed in this filing.
Risk Factors
- No financial data in this filing — all material news is deferred to the September 17 call.
- Prior 20-F flagged a funding gap and going-concern risk; the call may deliver negative news on cash position or pipeline delays.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001628280-26-061214 |
| Document: a260910_6k.htm | 0001628280-26-061214 |
| Document: 0001628280-26-061214-index-headers.html | 0001628280-26-061214 |
| Document: 0001628280-26-061214-index.html | 0001628280-26-061214 |
| Document: 0001628280-26-061214.txt | 0001628280-26-061214 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $1.54 | awaiting T+20 | — | $1.46 (−5.19%) |
Oct 21, 2026 6d ago | 6-K | $1.57 | awaiting T+20 | — | $1.46 (−7.01%) |
Oct 20, 2026 7d ago | 6-K | $1.58 | awaiting T+20 | — | $1.46 (−7.48%) |
Sep 17, 2026 5w ago | 6-K | $1.91 $1.48 | ▼ −22.51% | ▼ −23.97% | $1.46 (−23.56%) |
Sep 17, 2026 5w ago | 6-K | $1.91 $1.48 | ▼ −22.51% | ▼ −23.97% | $1.46 (−23.56%) |
Sep 17, 2026 5w ago | 6-K | $1.91 $1.48 | ▼ −22.51% | ▼ −23.97% | $1.46 (−23.56%) |
Sep 16, 2026 5w ago | Press Release | $1.91 $1.48 | ▼ −22.51% | ▼ −23.97% | $1.46 (−23.56%) |
Sep 10, 2026 6w ago | 6-K | $1.88 $1.48 | ▼ −21.28% | ▼ −23.40% | $1.46 (−22.34%) |
Sep 2, 2026 7w ago | 6-K | $2.17 $1.63 | ▼ −24.88% | ▼ −24.80% | $1.46 (−32.72%) |
Aug 14, 2026 10w ago | 6-K | $2.18 $1.85 | ▼ −15.14% | ▼ −13.15% | $1.46 (−33.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers